Bunnik, The Netherlands,18 February 2008: AM-Pharma B.V., the
biopharmaceutical company developing optimised endogenous proteins and
peptides to combat disease, today announced the appointment of Jacques Arend
as Vice President of Clinical Development.
Jacques Arend MD brings to the position a wealth of over twenty years of
international experience in medical and clinical development. His previous
work experience includes clinical development positions at SmithKline Beecham,
Yamanouchi, Novo Nordisk, Grünenthal, with his most recent position at Kendle
where he was the Medical Director for the Phase I and Clinical Pharmacology
Unit.
Jacques Arend MD replaces Chief Medical Officer Luiz Porto MD, who will remain
involved with AM-Pharma as Clinical Regulatory Consultant.
Bart Wuurman, CEO commented: “We are very pleased that Jacques, with his
outstanding experience in clinical development, has joined our team in the key
position of VP Clinical Development. During the next 18 months, we expect to
finalise four Phase IIa clinical trials which aim to confirm proof of concept
for two of our products and further add to the value of AM-Pharma.”
Jacques Arend added: ”The two specialist hospital care products AM-Pharma is
developing have the potential to make a significant impact on the treatment of
Infectious Diseases, Acute Renal Failure and Ulcerative Colitis. I am looking
forward to joining AM-Pharma and assisting in the development of these
products and the company’s pipeline.”
-ends-
Notes to editors:
About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and
clinical development of novel compounds in the field of specialist hospital
care. Its two clinical Phase II products are based on endogenous molecules
which have been optimised to combat disease.
Last year AM-Pharma announced positive results in two Phase IIa studies with
bovine Alkaline Phosphatase in Acute Renal Failure and severe Ulcerative
Colitis. A second Phase IIa confirmatory trial with bovine Alkaline
Phosphatase in Acute Renal Failure is about to start. In parallel, AM-Pharma
has started GMP manufacturing of a human recombinant Alkaline Phosphatase.
Anti-Microbial Peptide hLF1-11 was shown to be safe in Phase I trials. Phase
IIa studies in treatment of drug resistant hospital acquired bacterial
infections and for treatment of systemic Candida infections are expected to
start this summer.
Now that Proof of Concept has been established for bovine derived Alkaline
Phosphatase in Acute Renal Failure and Ulcerative Colitis, AM-Pharma has
started discussions with potential world-wide development and marketing
partners for its products while further safety and efficacy data are being
collected in developmental Phase II clinical trials.
AM-Pharma is based in Bunnik, The Netherlands with a staff of 20. The company
is financed by, amongst others, Forbion Capital Partners, Inventages Venture
Capital and Theratase plc.
For further information, please contact
College Hill – Life Sciences
Adam Michael / Justine Lamond / Holly Griffiths
Tel: +44 (0)20 7866 7857
ampharma@collegehill.com
AM-Pharma
CEO Bart Wuurman
Tel: +31 (0)30 2289222
www.am-pharma.com
